Sarad Kumar Mishra

Prof. Dr. Sarad Kumar Mishra


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2017 in Briefings in Functional Genomics
Verified
Journal Article
Closed access
PDF file
Vivek Dhar DwivediVivek Dhar Dwivedi
Vivek Dhar Dwivedi
ITIndra Prasad Tripathi
Indra Prasad Tripathi
RTRamesh Chandra Tripathi
Ramesh Chandra Tripathi
SBShiv Bharadwaj
Shiv Bharadwaj
SMSarad Kumar Mishra
Sarad Kumar Mishra
The genome of a pathogenic organism possesses a specific order of nucleotides that contains not only information about the synthesis and expression of proteomes, which are required for its growth and survival, but also about its evolution. Inhibition of any particular protein, which is required for the survival of that pathogenic organism, can be used as a potential therapeutic target for the development of effective drugs to treat its infections. In this review, the genomics, proteomics and evolution of dengue virus have been discussed, which will be helpful in better understanding of its origin, growth, survival and evolution, and may contribute toward development of new efficient anti-dengue drugs.

4 March 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
Vivek Dhar DwivediVivek Dhar Dwivedi
Vivek Dhar Dwivedi
SBShiv Bharadwaj
Shiv Bharadwaj
SASumbul Afroz
Sumbul Afroz
NKNooruddin Khan
Nooruddin Khan
MAMairaj Ahmed Ansari
Mairaj Ahmed Ansari
SKSang G. Kang
Sang G. Kang
Dengue virus (DENV) serine protease enzyme, i.e. NS2B-NS3pro (non-structural protein 2B-non-structural protein 3) has been approved as prime drug target for the drug discovery against dengue infection, because of its essential role in viral replication. This study demonstrates the potential of bioflavonoids from Azadirachta indica against dengue infection using computational and experimental approach. Initially, 49 bioflavonoids reported in Azadirachta indica were collected and virtually screened on the catalytic triad of DENV protease, results in the identification of kaempferol-3-O-rutinoside (-9.555 kcal/mol), rutin (-9.324 kcal/mol), hyperoside (-7.879 kcal/mol), and epicatechin (-7.622 kcal/mol) as potent viral protease inhibitors against reference compound quercetin (-6.94 kcal/mol). Subsequently, these docked complexes were analyzed for the stability via molecular dynamics simulations and free binding energy calculations, suggested the considerable stability of selected bioflavonoids with viral protease. Additionally, density functional theory and ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) analysis indicated the least chemical reactivity and considerable medicinal properties, respectively for the screened bioflavonoids by comparison to quercetin. Accordingly, kaempferol 3-O-β-rutinoside and epicatechin were evaluated at various concentrations for cell viability (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay) and in vitro antiviral activity (focus forming unit assay) against DENV-2 strain. The antiviral assay showed dose dependent inhibition of DENV-2 infectivity by the selected compounds while maximum 77.7% and 66.2% viral inhibition were recorded for 100 µM kaempferol 3-O-β-rutinoside and 1000 µM epicatechin, respectively without significant cell toxicity. These results suggested the potential of bioflavonoids from Azadirachta indica in the development of effective drug against dengue infection.

7 April 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
SBShiv Bharadwaj
Shiv Bharadwaj
ARAkhilesh Kumar Rao
Akhilesh Kumar Rao
Vivek Dhar DwivediVivek Dhar Dwivedi
Vivek Dhar Dwivedi
SMSarad Kumar Mishra
Sarad Kumar Mishra
Umesh YadavaUmesh Yadava
Umesh Yadava
Recent Zika virus (ZIKV) outbreak and association with human diseases such as neurological disorders have raised global health concerns. However, in the absence of an approved anti-ZIKV drug has generated urgency for the drug development against ZIKV infection. Here, structure-based virtual screening of 8589 bioactive compounds screened at the substrate-binding site of ZIKV nonstructural 5 (NS5)-based structure N-terminal methyltransferase (MTase) domain followed by ADMET (absorption, distribution, metabolism, excretion and toxicity) profiling concluded the four potential lead inhibitors, i.e. (4-acetylamino-benzenesulfonylamino)-acetic acid (F3342-0450), 3-(5-methylfuran-2-yl)-N-(4-sulfamoylphenyl)propanamide (F1736-0142), 8-(2-hydroxy-ethylamino)-1,3-dimethyl-7-(3-methyl-benzyl)-3,7-dihydro-purine-2,6-dione (F0886-0080) and N-[4-(aminosulfonyl)phenyl]-2,3-dihydro-1,4-benzodioxine-2-carboxamide (F0451-2187). Collectively, extra precision docking and Density Functional Theory calculations studies identified the F3342-0450 molecule having strong interactions on the active site of MTase, was further supported by molecular dynamics simulation, binding affinity and hybrid QM/MM calculations, suggest a new drug molecule for the antiviral drug development against ZIKV infection.

15 January 2013 in Preparative Biochemistry & Biotechnology
Verified
Journal Article
Closed access
RMRuckminee Mall
Ruckminee Mall
GNGaurav Naik
Gaurav Naik
UMUsha Mina
Usha Mina
SMSarad Kumar Mishra
Sarad Kumar Mishra
A soluble and thermostable peroxidase enzyme (POD) was extracted from the leaf of Citrus medica. The enzyme was purified 15.10-fold with a total yield of 28.6% by ammonium sulfate precipitation followed by Sephadex G-100 gel filtration chromatography. The purified enzyme came as a single band on native polyacrylamide gel electrophoresis (PAGE) as well as sodium dodecyl sulfate (SDS) PAGE. The molecular mass of the enzyme was about 32 kD as determined by SDS-PAGE. The enzyme was optimally active at pH 6.0 and 50°C temperature. The enzyme was active in wide range of pH (5.0–8.0) and temperature (30–80°C). From the thermal inactivation studies in the range of 60–75°C, the half-life (t1/2) values of the enzyme ranged from 8 to 173 min. The inactivation energy (Ea) value of POD was estimated to be 21.7 kcal mol−1. The Km values for guaiacol and H2O2 were 8 mM and 1.8 mM, respectively. This enzyme was activated by some metals and reagents such as Ca2+, Cu2+, Mg2+, Co2+, ferulic acid, and indole acetic acid (IAA), while it was inhibited by Fe2+, Zn2+, Hg2+, and Mn2+, L-cysteine, L-proline, and protocatechuic acid.

27 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
AOAnupama Ojha
Anupama Ojha
SJSonali Jaiswal
Sonali Jaiswal
PBPriyanka Bharti
Priyanka Bharti
SMSarad Kumar Mishra
Sarad Kumar Mishra
Along with the extensive improvement in tumor biology research and different therapeutic developments, cancer remains a dominant and deadly disease. Tumor heterogeneity, systemic toxicities, and drug resistance are major hurdles in cancer therapy. Chemotherapy, radiotherapy, phototherapy, and surgical therapy are some prominent areas of cancer treatment. During chemotherapy for cancer, chemotherapeutic agents are distributed all over the body and also damage normal cells. With advancements in nanotechnology, nanoparticles utilized in all major areas of cancer therapy offer the probability to advance drug solubility, and stability, extend drug half-lives in plasma, reduce off-target effects, and quintessence drugs at a target site. The present review compiles the use of different types of nanoparticles in frequently and recently applied therapeutics of cancer therapy. A recent area of cancer treatment includes cancer stem cell therapy, DNA/RNA-based immunomodulation therapy, alteration of the microenvironment, and cell membrane-mediated biomimetic approach. Biocompatibility and bioaccumulation of nanoparticles is the major impediment in nano-based therapy. More research is required to develop the next generation of nanotherapeutics with the incorporation of new molecular entities, such as kinase inhibitors, siRNA, mRNA, and gene editing. We assume that nanotherapeutics will dramatically improve patient survival, move the model of cancer treatment, and develop certainty in the foreseeable future.

31 July 2013 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
SGSatya Prakash Gupta
Satya Prakash Gupta
SYSharawan Yadav
Sharawan Yadav
NSNaveen Kumar Singhal
Naveen Kumar Singhal
MTManindra Nath Tiwari
Manindra Nath Tiwari
SMSarad Kumar Mishra
Sarad Kumar Mishra
MSMahendra Pratap Singh
Mahendra Pratap Singh